Overview

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection

Status:
Completed

Trial end date:
2014-01-24

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate the safety, tolerability, and antiviral activity of velpatasvir (formerly GS-5816) in HCV treatment naive participants with genotypes 1-6.

Phase:

Phase 1

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Antiviral Agents
Velpatasvir